Fig. 4From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapyKaplan–Meier analyses for progression-free survival a and overall survival b of IIIB-IV NSCLC patients according to the SUV_LMR score (0,1 and 2)Back to article page